The objective of the study was to investigate ulcerative colitis management through oral administration of acarbose.
Introduction
Ulcerative Colitis (UC) is a chronic inflammatory disease affecting the rectum and the colon to a variable extent and exerts a substantially negative impact on the quality of life of affected patients. Some causes are still not known. Patients ailing from this disease have a 10% increased risk of developing colorectal carcinoma. Some progress has been made in the treatment of UC in the past few decades and many conventional drugs and therapies such as sulfasalazine, corticosteroids and The expression of UC is generally believed to be an interplay of environmental, genetic and immunological factors (Fries et al., 2011) . However, there is still not an integrated concept which explains the initiating event(s) and/or fundamental abnormalities in UC related to the pathophysiological changes. It does seem certain that UC is amplified and propagated by an uncontrolled and sustained host immune response, as the disease is paralleled by an extensive inflammatory infiltrate in the lamina propria, consisting of polymorphonuclear neutrophils, eosinophils and plasma cells. The effects from such excessive and enduring mucosal immune activation and tissue injury are still not fully confirmed. There are only a limited number of effects or mechanisms, including reactive oxygen metabolites (ROM), which may be responsible for the excessive cellular/tissue damage, chronic inflammation and destruction of normal tissue that is observed in UC ( Karp and Koch, 2006) . Impaired antioxidant activity is implicated as one of pathogenic causes of UC. Inflamed tissue generates hydroxyl radicals, most cytotoxic reactive oxygen species (ROS), which up-regulate TNF-α expression through NF-kB, signalling the
